The G2 checkpoint inhibitor CBP-93872 increases the sensitivity of colorectal and pancreatic cancer cells to chemotherapy
Fig 3
CBP-93872 inhibits maintenance of G2 and S-phase checkpoints.
(A, B) HT29 cells were treated with oxaliplatin (30 μM) (A), or cisplatin (30 μM) (B) in the presence or absence of CBP-93872 (50 μM). Nocodazole (500 nM) was added to inhibit the exit of cells from mitosis. Cells were harvested at 48 hrs, fixed, and stained with anti-H3-pS10 antibodies to determine the mitotic index. Mitotic indices (left) and typical examples (right) are shown. Data are presented as means ± SD (n = 3). Statistical significance was calculated using Student’s t-test (*, p < 0.01). ((C) Panc-1 cells were treated with gemcitabine (0.1 μM) in the presence or absence of CBP-93872 (200 μM) with nocodazole (500 nM).